Showing results (101-110 of 151) with videos related to
Sort By:
Pageof 16
NPJ Breast Cancer|November 9, 2019
If we build it they will come: targeting the immune response to breast cancerMargaret E Gatti-Mays, Justin M Balko, Sofia R Gameiro, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II StudySara M Tolaney, Kevin Kalinsky, Virginia G Kaklamani, et al.Nature Cancer|October 29, 2021
Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapyJason I Griffiths, Jinfeng Chen, Patrick A Cosgrove, et al.NPJ Breast Cancer|June 10, 2022
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysisLisa A Carey, Delphine Loirat, Kevin Punie, et al.Cancer|March 24, 2017
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)Kevin Kalinsky, Sandra Lee, Krista M Rubin, et al.European Journal of Cancer (Oxford, England : 1990)|November 15, 2022
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancerSibylle Loibl, Delphine Loirat, Sara M Tolaney, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 28, 2016
Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The ¡Cocinar Para Su Salud! Randomized Controlled TrialHeather Greenlee, Ann Ogden Gaffney, A Corina Aycinena, et al.The Journal of Clinical Investigation|March 26, 2024
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancersYueming Zhu, Anupam Banerjee, Ping Xie, et al.Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.The New England Journal of Medicine|January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast CancerSara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.Pageof 16